

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/RD9FDCBA3633EN.html>

Date: July 2022

Pages: 179

Price: US\$ 2,000.00 (Single User License)

ID: RD9FDCBA3633EN

Abstracts

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 51, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).

The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies

Involved in Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued
Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product

Development Milestones

Featured News & Press Releases

Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the
Radiation Research Society 2022 annual meeting

Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the
Radiation Research Society 2022 annual meeting

Jul 21, 2022: Eckert & Ziegler Affiliate receives further NIAID funding for clinical
development

Apr 26, 2022: New studies published comparing BIO 300 to Neulasta for acute radiation
syndrome

Mar 24, 2022: Tanner Pharma increases Europe-based inventory of Leukine to expand
availability and enhance response to potential radiation exposure due to the ongoing
Conflict in Ukraine

Dec 01, 2021: Statera Biopharma announces FDA lifts clinical hold on entolimod

Nov 18, 2021: Enveric Biosciences announces positive preclinical data for EV102 Radiodermatitis Drug Candidate

Sep 22, 2021: Humanetics announces results from phase 1 trial of BIO 300 oral powder

Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders

Jun 08, 2021: Affiliate receives additional NIAID funding to advance pharmaceutical development

Feb 18, 2021: Partner Therapeutics announces publication of two studies demonstrating Leukine improves survival in Acute Radiation Syndrome (ARS)

Feb 08, 2021: Enzychem Lifesciences announces poster presentation at AACR Virtual Annual Meeting 2021

Jan 26, 2021: Enzychem Lifesciences receives NASA grant funding to evaluate EC-18 as a protective agent for radiation and pathogen-induced tissue damage and inflammation in space

Oct 20, 2020: Humanetics presents at the Annual Radiation Research Society meeting

Oct 15, 2020: Meabco's drug candidate efficiently mitigates radiation-induced gastrointestinal syndrome in mice

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, 2022

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/RD9FDCBA3633EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RD9FDCBA3633EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970